+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Myeloma Drug"

Global Multiple Myeloma Drugs Market 2023-2027 - Product Thumbnail Image

Global Multiple Myeloma Drugs Market 2023-2027

  • Report
  • October 2022
  • 120 Pages
  • Global
From
From
From
From
From
From
Multiple Myeloma: Epidemiology Forecast to 2027 - Product Thumbnail Image

Multiple Myeloma: Epidemiology Forecast to 2027

  • Report
  • March 2019
  • 42 Pages
  • Global
From
From
Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2020 - Product Thumbnail Image

Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 2289 Pages
  • Global
From
From
From
From
Loading Indicator

Myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is part of a larger group of cancers known as leukemias. Treatment for myeloma typically involves a combination of chemotherapy, radiation therapy, and targeted therapies. In recent years, the development of new drugs has revolutionized the treatment of myeloma. These drugs are designed to target specific proteins or pathways that are involved in the growth and spread of the cancer. The myeloma drug market is a rapidly growing segment of the larger leukemia drug market. It is driven by the development of new drugs that are more effective and have fewer side effects than traditional treatments. These drugs are often used in combination with other treatments, such as chemotherapy and radiation therapy, to maximize their effectiveness. Some of the major companies in the myeloma drug market include Bristol-Myers Squibb, Celgene, Novartis, and Pfizer. These companies are at the forefront of developing new treatments for myeloma and are actively researching new drugs and therapies. Show Less Read more